Regulatory Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars Big Molecule WatchOn May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S.Read full story pharminent June 4, 2026 (Last updated: June 5, 2026) Big Molecule Watch On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Read full story Post navigation Previous: SCOTUS backs generic firm Hikma in skinny label disputeNext: Pfizer signs licence agreement with Chai for AI drug discovery Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026